Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer‐cell malignancies

BCX1777 (forodesine), a novel purine nucleoside phosphorylase inhibitor, induces apoptosis, mainly in T cells. To evaluate the safety, tolerability, and pharmacokinetics of BCX1777, we conducted a phase I study in patients with relapsed or refractory peripheral T/natural killer‐cell malignancies. El...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Sci
Auteurs principaux: Ogura, Michinori, Tsukasaki, Kunihiro, Nagai, Hirokazu, Uchida, Toshiki, Oyama, Takashi, Suzuki, Tatsuya, Taguchi, Jun, Maruyama, Dai, Hotta, Tomomitsu, Tobinai, Kensei
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2012
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7659180/
https://ncbi.nlm.nih.gov/pubmed/22448814
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1349-7006.2012.02287.x
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires